Data Visualization•8 min read•Updated 2026-04-03

    GLP-1 Drug Pipeline Visual: Every Weight Loss Medication in Development (2026)

    Visual map of every GLP-1 and weight loss medication currently in clinical trials, from Phase 1 through FDA approval. See what is coming next after semaglutide and tirzepatide.

    More on Data Visualization

    View all Data Visualization articles

    Next-Gen Drugs

    Future medications

    Retatrutide Guide

    Triple agonist

    Pipeline Overview

    Over a dozen weight loss medications are in clinical development. The next 2-3 years will bring oral options, triple agonists, and combination therapies. Meanwhile, semaglutide ($99/mo) and tirzepatide ($125/mo) are available now through Trimi.

    Drug Pipeline Map

    Retatrutide (Eli Lilly)

    Triple: GLP-1/GIP/Glucagon

    Phase 32027-2028
    24%+

    weight loss

    Orforglipron (Eli Lilly)

    Oral GLP-1 agonist

    Phase 32026-2027
    14-15%

    weight loss

    Survodutide (Boehringer)

    Dual: GLP-1/Glucagon

    Phase 32027-2028
    18-19%

    weight loss

    CagriSema (Novo Nordisk)

    Semaglutide + Cagrilintide

    Phase 32027
    22-25%

    weight loss

    Amycretin (Novo Nordisk)

    Oral: GLP-1/Amylin

    Phase 22028-2029
    13% (Phase 1)

    weight loss

    Pemvidutide (Altimmune)

    Dual: GLP-1/Glucagon

    Phase 22028+
    15%

    weight loss

    Pipeline data as of April 2026. Approval timelines are estimates and subject to change based on trial results and FDA review.

    Available Now at Trimi

    Semaglutide

    $99/mo

    FDA-approved. Available now.

    Tirzepatide

    $125/mo

    FDA-approved. Available now.

    Retatrutide

    Ask us

    Compounded. Ask about availability.

    Medical Disclaimer: Pipeline drugs are investigational and not yet FDA-approved for weight loss. This information is for educational purposes. Consult your provider about currently available options.

    Frequently Asked Questions

    What weight loss drugs are coming after Wegovy and Mounjaro?

    Several next-generation drugs are in development: retatrutide (triple agonist, Phase 3), orforglipron (oral GLP-1, Phase 3), amycretin (oral dual agonist, Phase 2), survodutide (dual agonist, Phase 3), and CagriSema (combination, Phase 3). Multiple oral options are expected by 2027-2028.

    When will retatrutide be FDA approved?

    Retatrutide is in Phase 3 trials (TRIUMPH program) with results expected in 2026-2027. If successful, FDA approval could come in late 2027 or 2028. Compounded versions may be available sooner through providers like Trimi.

    Will oral GLP-1 pills replace injections?

    Oral options like orforglipron and amycretin are showing promising results. While convenience is higher, early data suggests injectable forms may still produce slightly higher weight loss. Both forms will likely coexist to serve different patient preferences.

    Which pipeline drug looks most promising?

    Retatrutide has shown the highest weight loss in trials to date (24%+ at 48 weeks). Amycretin is notable as an oral medication matching injectable GLP-1 efficacy. CagriSema combines two proven compounds for potentially enhanced results.

    Why Wait? Start Treatment Today

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 5, 2026

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Was this article helpful?

    Keep Reading

    GLP-1

    GLP-1 and Pregnancy Planning

    When and how to start semaglutide or tirzepatide after pregnancy. Postpartum GLP-1 guide covering breastfeeding safety, timing, and realistic weight loss expectations.

    10 minRead More
    GLP-1

    Buy Tirzepatide in Texas

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    10 minRead More
    GLP-1

    GLP-1 Success: Post-Pregnancy

    Guide for new mothers considering semaglutide or tirzepatide for postpartum weight loss. Covers timing after breastfeeding, managing treatment with a newborn, and practical tips for busy parents.

    10 minRead More
    GLP-1

    Buy Tirzepatide in California

    Buy compounded semaglutide online in California for just $99/month. Learn about California telehealth laws, compounding pharmacy regulations, and how to start GLP-1 weight loss treatment today.

    10 minRead More